Multiple Myeloma

Videos

Dr Laubach Reviews Phase 2 GRIFFIN Study Results in Newly Diagnosed MM

01/10/2022

Jacob Laubach, MD, MPP, Dana-Farber Cancer Institute, discusses new results from the Phase 2 GRIFFIN study of daratumumab as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the ASH 2021 Annual Meeting.

Jacob Laubach, MD, MPP,...

01/10/2022

Oncology

Podcasts

Dr Wildgust Reviews CASSIOPEIA Phase 3 Results in First-Line MM

12/15/2021

Mark Wildgust, PhD, highlights results from the Phase 3 CASSIOPEIA study of daratumumab as maintenance therapy in first-line MM treatment after stem cell transplant, presented at the 2021 Annual ASH Meeting.

Mark Wildgust, PhD, highlights...

12/15/2021

Oncology

Podcasts

Dr Wildgust Discusses Racial Disparities in Treatment Patterns, Outcomes in MM

12/14/2021

Mark Wildgust, PhD, reviews real-world evidence examining potential healthcare disparities- highlighting patient characteristics, treatment patterns and outcomes for Black and White patients with multiple myeloma who initiated treatment with...

Mark Wildgust, PhD, reviews...

12/14/2021

Oncology

Videos

Dr Fonseca Highlights Phase 2 GRIFFIN Study Results for Newly Diagnosed MM

12/13/2021

Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.

Rafael Fonseca, MD, Mayo Clinic,...

12/13/2021

Oncology

Conference Coverage

Safety and Tolerability Analysis of Melflufen plus Dexamethasone in Patients with Relapsed/Refractory MM

12/01/2021

Melfulen plus dexamethasone shows consistent safety and tolerability when compared to pomalidomide and dexamethasone.

Melfulen plus dexamethasone...

12/01/2021

Oncology

Conference Insider

Combination Daratumumab and Dexamethasone Shows Promising Efficacy in Patients with RRMM and Severe Renal Impairment

12/01/2021

Daratumumab, in combination with dexamethasone, demonstrated promising efficacy with manageable safety in patients with RRMM and severe renal impairment or on dialysis.

Daratumumab, in combination with...

12/01/2021

Oncology

Conference Coverage

Ixazomib and Daratumumab Demonstrate Tolerable Safety for Elderly Patients with Relapsed/Refractory MM

12/01/2021

When given to elderly and frail patients with relapsed/refractory MM, combination ixazomib and daratumumab, without dexamethasone, showed favorable safety.

When given to elderly and frail...

12/01/2021

Oncology

Conference Coverage

Ruxolitinib with Steroids Shows Promise in Patients with Relapsed/Refractory MM

11/30/2021

Ruxolitinib in combination with steroids is a promising treatment option for heavily pretreated patients with relapsed/refractory MM.

Ruxolitinib in combination with...

11/30/2021

Oncology

Conference Coverage

Venetoclax Plus Daratumumab and Dexamethasone Yields Tolerable Safety in Patients with Relapsed/Refractory MM

11/29/2021

Preliminary results from a phase 1/2 trial showed that venetoclax plus daratumumab and dexamethasone demonstrates a tolerable safety profile in patients with relapsed/refractory MM.

Preliminary results from a phase...

11/29/2021

Oncology

Conference Coverage

Adding Venetoclax to Bortezomib and Dexamethasone Improves PFS in Patients with Relapsed/Refractory MM

11/28/2021

Results from the BELLINI trial showed adding venetoclax to bortezomib and dexamethasone showed improved PFS but increased mortality in patients with relapsed/refractory MM.

Results from the BELLINI trial...

11/28/2021

Oncology